TCL Archive Funding Exceptions, Skipovers, While Limited At NCI, Become Crucial Issues; NCAB To Be Brief On Details January 7, 1983
TCL Archive FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March. January 21, 2005
TCL Archive In Brief: NCAB ask Force Supports Group-Led Data and Safety Monitoring Committees August 19, 1994
TCL Archive Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit. October 14, 2005
